


- 70 -

What is claimed is:

1. Use of a composition comprising
 (i) at least one metal complex of formula (1)

5



wherein Me is manganese, titanium, iron, cobalt, nickel or copper,

X is a coordinating or bridging radical,

10 n and m are each independently of the other an integer having a value of from 1 to 8,


p is an integer having a value of from 0 to 32,

z is the charge of the metal complex,

Y is a counter-ion,

q = z/(charge of Y), and

15 L is a ligand of formula (2)



wherein

Q₁ is N or CR₁₀,

Q₂ is N or CR₁₁,

20 R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are each independently of the others hydrogen; unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl; cyano; halogen; nitro; -COOR₁₂ or -SO₃R₁₂ wherein

R₁₂ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl;

25 -SR₁₃, -SO₂R₁₃ or -OR₁₃ wherein

R₁₃ is in each case hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl;

-NR₁₄R₁₅; -(C₁-C₆alkylene)-NR₁₄R₁₅; -N[⊕]R₁₄R₁₅R₁₆; -(C₁-C₆alkylene)-N[⊕]R₁₄R₁₅R₁₆; -N(R₁₃)-(C₁-C₆alkylene)-NR₁₄R₁₅; -N[(C₁-C₆alkylene)-NR₁₄R₁₅]₂; -N(R₁₃)-(C₁-C₆alkylene)-N[⊕]R₁₄R₁₅R₁₆;

- 71 -

$-N[(C_1-C_8\text{alkylene})-N^{\oplus}R_{14}R_{15}R_{16}]_2$; $-N(R_{13})-N-R_{14}R_{15}$ or $-N(R_{13})-N^{\oplus}R_{14}R_{15}R_{16}$, wherein

R_{13} is as defined above and

R_{14} , R_{15} and R_{16} are each independently of the other(s) hydrogen or unsubstituted or substituted C_1-C_{18} alkyl or unsubstituted or substituted aryl, or

5 R_{14} and R_{15} , together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms, and

(ii) at least one polyphosphonate

as oxidation catalyst for peroxide compounds.

10

2. Use according to claim 1, wherein Me is manganese, which is in oxidation state II, III, IV or V.

3. Use according to either claim 1 or claim 2, wherein

15 X is CH_3CN , H_2O , F^- , Cl^- , Br^- , HOO^- , O_2^{2-} , O^{2-} , $R_{17}COO^-$, $R_{17}O^-$, $LMeO^-$ or $LMeOO^-$, wherein R_{17} is hydrogen or unsubstituted or substituted C_1-C_{18} alkyl or aryl, and L and Me are as defined in claim 1.

4. Use according to any one of claims 1 to 3, wherein

20 Y is $R_{17}COO^-$, ClO_4^- , BF_4^- , PF_6^- , $R_{17}SO_3^-$, $R_{17}SO_4^-$, SO_4^{2-} , NO_3^- , F^- , Cl^- , Br^- or I^- , wherein R_{17} is hydrogen or unsubstituted or substituted C_1-C_{18} alkyl or aryl.

5. Use according to any one of claims 1 to 4, wherein

n is an integer having a value of from 1 to 4, especially 1 or 2.

25

6. Use according to any one of claims 1 to 5, wherein

m is an integer having a value of 1 or 2, especially 1.

7. Use according to any one of claims 1 to 6, wherein

30 p is an integer having a value of from 0 to 4, especially 2.

8. Use according to any one of claims 1 to 7, wherein

z is an integer having a value of from 8- to 8+.

- 72 -

9. Use according to claim 1 to 8, wherein

R₅ is C₁-C₁₂alkyl; phenyl unsubstituted or substituted by C₁-C₄alkyl, C₁-C₄alkoxy, halogen, cyano, nitro, carboxy, sulfo, hydroxy, amino, N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, N-phenylamino, N-naphthylamino, phenyl, phenoxy or by naphthyloxy; cyano; halogen; nitro; -COOR₁₂ or -SO₃R₁₂

wherein R₁₂ is in each case hydrogen, a cation, C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above; -SR₁₃, -SO₂R₁₃ or -OR₁₃

wherein R₁₃ is in each case hydrogen, C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above; -N(R₁₃)-NR₁₄R₁₅

wherein R₁₃ is as defined above and R₁₄ and R₁₅ are each independently of the other hydrogen, unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above,

or R₁₄ and R₁₅, together with the nitrogen atom linking them, form an unsubstituted or C₁-C₄alkyl-substituted pyrrolidine, piperidine, piperazine, morpholine or azepane ring;

-NR₁₄R₁₅ or -N[®]R₁₄R₁₅R₁₆ wherein R₁₄, R₁₅ and R₁₆ are each independently of the other(s) hydrogen, unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above,

or R₁₄ and R₁₅, together with the nitrogen atom linking them, form an unsubstituted or

C₁-C₄alkyl-substituted pyrrolidine, piperidine, piperazine, morpholine or azepane ring; N-mono- or N,N-di-C₁-C₄alkyl-N[®]R₁₄R₁₅R₁₆ unsubstituted or substituted by hydroxy in the alkyl moiety,


wherein R₁₄, R₁₅ and R₁₆ are each independently of the others hydrogen, unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above,

or R₁₄ and R₁₅, together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring which is unsubstituted or substituted by at least one C₁-C₄alkyl or by at least one unsubstituted C₁-C₄alkoxy and/or substituted C₁-C₄alkyl, wherein the nitrogen atom may be quaternised; N-mono- or

N,N-di-C₁-C₄alkyl-NR₁₄R₁₅ unsubstituted or substituted by hydroxy in the alkyl moiety, wherein R₁₄ and R₁₅ may have any one of the above meanings.

10. Use according to claim 1 to 9, wherein L have the following formula (3)

- 73 -




wherein

R'₃ and R'₇ are independently from each other hydrogen; C₁-C₄alkoxy; hydroxy; N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein
 5 the nitrogen atoms, especially the nitrogen atoms that are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C₁-C₄alkyl, wherein the amino groups may be quaternised,

R'₅ is C₁-C₄alkoxy; hydroxy; N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted
 10 by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms that are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C₁-C₄alkyl, wherein the amino groups may be quaternised.

15 11. Use according to claim 1 to 10, wherein L have the following formula (3)



wherein



R'₃ and R'₇ are independently from each other hydrogen; C₁-C₄alkoxy; hydroxy; N-mono- or
 20 N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms that are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C₁-C₄alkyl, wherein the amino groups may be quaternised,

25 R'₅ is C₁-C₄alkoxy; hydroxy; N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms that

- 74 -

are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C₁-C₄alkyl, wherein the amino groups may be quaternised, with the proviso that


- 5 (i) at least one of the substituents R'₃, R'₅ and R'₇ is one of the radicals



wherein R₁₅ and R₁₆ are independently from each other hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl and

- 10 wherein the unbranched or branched alkylene group may be unsubstituted or substituted, and wherein the C₁-C₄alkyl groups, which are branched or unbranched independently of one another, may be unsubstituted or substituted and wherein the piperazine ring may be unsubstituted or substituted.

- 15 12. Use according to claim 1 to 9, wherein L have the following formula (4) and/or (5)



wherein

- 20 R'₅ is C₁-C₄alkoxy; Cl; hydroxy; phenyl; phenyl substituted by OC₁-C₂alkyl, OH or C₁-C₄alkyl; N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety; or -NR₁₄R₁₅; -(C₁-C₆alkylene)-NR₁₄R₁₅; -N(R₁₃)-(C₁-C₆alkylene)-NR₁₄R₁₅; -N[(C₁-C₆alkylene)-NR₁₄R₁₅]₂; or -N(R₁₃)-N-R₁₄R₁₅, wherein R₁₃ is hydrogen; C₁-C₁₂alkyl or unsubstituted phenyl or phenyl substituted by (substituted in the alkyl moiety by hydroxy) N-mono- or

- 75 -

N,N-di-C₁-C₄alkylamino-, N-phenylamino-, N-naphthylamino-, phenyl-, phenoxy- or naphthyloxy, and

R₁₄ and R₁₅ are each independently of the other hydrogen, unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or

R₁₄ and R₁₅, together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring that is unsubstituted or substituted by at least one unsubstituted C₁-C₄alkyl and/or substituted C₁-C₄alkyl, especially a pyrrolidine, piperidine, piperazine, morpholine or azepane ring, and


R'₃ and R'₇ are each independently of the other hydrogen; C₁-C₄alkoxy; Cl; hydroxy; phenyl; phenyl substituted by OC₁-C₂alkyl, OH or C₁-C₄alkyl; N-mono- or N,N-di-C₁-C₄alkylamino substituted by hydroxy in the alkyl moiety; or -NR₁₄R₁₅; - (C₁-C₆alkylene)-NR₁₄R₁₅; -N(R₁₃)-(C₁-C₆alkylene)-NR₁₄R₁₅; -N[(C₁-C₆alkylene)-NR₁₄R₁₅]₂; or -N(R₁₃)-N-R₁₄R₁₅, wherein

R₁₃ is hydrogen; C₁-C₁₂alkyl or unsubstituted phenyl or phenyl substituted by (substituted in the alkyl moiety by hydroxy) N-mono- or N,N-di-C₁-C₄alkylamino-, N-phenylamino-, N-naphthylamino-, phenyl-, phenoxy- or naphthyloxy, and

R₁₄ and R₁₅ are each independently of the other hydrogen; unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or


R₁₄ and R₁₅, together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring that is unsubstituted or substituted by at least one unsubstituted C₁-C₄alkyl and/or substituted C₁-C₄alkyl, especially a pyrrolidine, piperidine, piperazine, morpholine or azepane ring.

13. Use according to claim 1 to 9, wherein L have the following formula (4) and/or (5)




- 76 -

- wherein R'_3 and R'_7 are independently from each other hydrogen; C_1 - C_4 alkoxy; Cl; hydroxy; phenyl; phenyl substituted by OC_1 - C_2 alkyl, OH or C_1 - C_4 alkyl; N-mono- or N,N-di- C_1 - C_4 alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms that are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C_1 - C_4 alkyl, wherein the amino groups may be quaternised,
- R'_5 is C_1 - C_4 alkoxy; Cl; hydroxy; phenyl; phenyl substituted by OC_1 - C_2 alkyl, OH or C_1 - C_4 alkyl; N-mono- or N,N-di- C_1 - C_4 alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms that are not bonded to one of the rings A, B and/or C, may be quaternised; or a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C_1 - C_4 alkyl, wherein the amino groups may be quaternised,
- with the proviso that
- (i) at least one of the substituents R'_3 , R'_5 and R'_7 is one of the radicals



- wherein R_{15} and R_{16} are independently from each other hydrogen or unsubstituted or substituted C_1 - C_{18} alkyl or unsubstituted or substituted aryl and
- wherein the unbranched or branched alkylene group may be unsubstituted or substituted, and wherein the C_1 - C_4 alkyl groups, which are branched or unbranched independently of one another, may be unsubstituted or substituted and wherein the piperazine ring may be unsubstituted or substituted.
14. Use according to any of the preceeding claims wherein at least one polyphosphonate of the formula



- 77 -

wherein


R_{18} is $CH_2PO_3H_2$ or a water soluble salt thereof and

b is an integer of the value 0, 1, 2 or 3

is used.

5

15. Use according to any of the preceding claims wherein at least one the formula



wherein

10 R_{18} is $CH_2PO_3H_2$ or a water soluble salt thereof and

b is an integer of the value 1

is used.

15 16. Use according to any one of claims 1 to 15 for the bleaching of stains or of soiling on textile material, or for the prevention of redeposition of migrating dyes, or for the cleaning of hard surfaces.

20 17. Use according to any one of claims 1 to 15, wherein the metal complex compounds of formula (1) are used as catalysts for reactions using peroxo acids or their precursors for bleaching in the context of paper making.

18. Use according to any one of claims 1 to 15, wherein the metal complex compounds of formula (1) are used in detergent, cleaning, disinfecting or bleaching compositions.

25 19. Use according to claim 18, wherein the metal complex compounds of formula (1) are formed *in situ* in the detergent, cleaning, disinfecting or bleaching composition.

20. A detergent, cleaning, disinfecting or bleaching composition containing

- 30 I) from 0 to 50% by weight, preferably from 0 to 30% by weight, A) of at least one anionic surfactant and/or B) of a non-ionic surfactant,
II) from 0 to 70% by weight, preferably from 0 to 50% by weight, C) of at least one builder substance,

- 78 -

- III) 1 - 99 %, preferably 1 - 50 %, D) of at least one peroxide and/or at least one peroxide-forming substance,
- IV) 0.01 - 10% by weight, preferably 0.1 - 5% by weight E) of at least one polyphosphonate as defined in claims 14 and 15,
- 5 V) F) at least one metal complex compound of formula (1) as defined in claims 1 - 13 in an amount that, in the liquor, gives a concentration of from 0.5 to 100 mg/litre of liquor, preferably from 1 to 50 mg/litre of liquor, when from 0.5 to 20 g/litre of the detergent, cleaning, disinfecting or bleaching agent are added to the liquor, and
- VI) water ad 100% by weight,
- 10 wherein the percentages are in each case percentages by weight, based on the total weight of the composition.

21. A solid formulation containing

- a) from 1 to 99% by weight, preferably from 1 to 40% by weight, especially from 1 to 30% by weight, of at least one metal complex compound of formula (1) as defined in claims 1 - 13,
- 15 b) from 0.01 - 10% by weight, preferably 0.1 - 5% by weight, E) of at least one polyphosphonate as defined in claims 14 and 15,
- c) from 1 to 99% by weight, preferably from 10 to 99% by weight, especially from 20 to 80% by weight, of at least one binder,
- 20 d) from 0 to 20% by weight, especially from 1 to 20% by weight, of at least one encapsulating material,
- e) from 0 to 20% by weight of at least one further additive and
- f) from 0 to 20% by weight water.

25

22. A solid formulation according to claim 21, which is in the form of granules.